Digestive system dysfunction in cystic fibrosis: Challenges for nutrition therapy

Digestive and Liver Disease

Volumn 46, Issue 10, 2014, Pages 865-874

  Li, Li ^a   Somerset, Shawn ^b  

^a GRIFFITH UNIVERSITY   (Australia)

^b AUSTRALIAN CATHOLIC UNIVERSITY   (Australia)

Author keywords

Cystic fibrosis; Gut microbiota; Malabsorption; Maldigestion

Indexed keywords

AMINO ACID; BICARBONATE; BILE ACID; CHLORIDE; DISACCHARIDE; FAT; FATTY ACID; ION; LIPID; OMEGA 3 FATTY ACID; PANCREAS ENZYME; TRIACYLGLYCEROL LIPASE;

ABSORPTION; BACTERIAL OVERGROWTH; BRUSH BORDER; COLON FLORA; CYSTIC FIBROSIS; DIET THERAPY; DIGESTION; DIGESTIVE SYSTEM; DIGESTIVE SYSTEM DISEASE; DIGESTIVE SYSTEM FUNCTION DISORDER; ENERGY; ENTERITIS; ENZYME ACTIVITY; EPITHELIUM CELL; GALLBLADDER; GASTRIC HYPERACIDITY; GENE MUTATION; INFLAMMATION; INTESTINE; LIVER; MALABSORPTION; MUCUS; NUTRIENT; NUTRITION; PANCREAS; PANCREAS EXOCRINE INSUFFICIENCY; PH; PRIORITY JOURNAL; REGULATOR GENE; REVIEW; SUBSTITUTION THERAPY; TRANSMEMBRANE REGULATOR GENE; COMPLICATION; DIET SUPPLEMENTATION; EXOCRINE PANCREATIC INSUFFICIENCY; HUMAN; MALABSORPTION SYNDROMES; MICROBIOLOGY; PATHOPHYSIOLOGY; PROCEDURES;

CYSTIC FIBROSIS; DIETARY SUPPLEMENTS; EXOCRINE PANCREATIC INSUFFICIENCY; HUMANS; MALABSORPTION SYNDROMES; NUTRITION THERAPY;

EID: 84922259983     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.06.011     Document Type: Review

References (140)

1. Suaud L., Ruberstein R.C. The genetics of cystic fibrosis. Cystic fibrosis 2010, 1-10. Informa Healthcare. first ed. J.L. Allen, H.B. Panitch, R.C. Ruberstein (Eds.).
2. Melvin J.E. Chloride channels and salivary gland function. Critical Reviews in Oral Biology and Medicine 1999, 10:199-209.
3. Wilschanski M., Durie P.R. Patterns of GI disease in adulthood associated with mutations in the CFTR gene. Gut 2007, 56:1153-1163.
4. Whitcomb D., Lowe M. Human pancreatic digestive enzymes. Digestive Diseases and Sciences 2007, 52:1-17.
5. Taylor C.J., Aswani N. The pancreas in cystic fibrosis. Paediatric Respiratory Reviews 2002, 3:77-81.
6. Grapin-Botton A. Ductal cells of the pancreas. International Journal of Biochemistry and Cell Biology 2005, 37:504-510.
7. Strong T., Boehm K., Collins F. Localization of cystic fibrosis transmembrane conductance regulator mRNA in the human gastrointestinal tract by in situ hybridization. Journal of Clinical Investigation 1994, 93:347-354.
8. - channels and luminal anion exchangers. Gastroenterology 2011, 141. 2228-39.e6.
9. Ferrone M., Raimondo M., Scolapio J.S. Pancreatic enzyme pharmacotherapy. Pharmacotherapy 2007, 27:910-920.
10. Layer P., Keller J. Pancreatic enzymes: secretion and luminal nutrient digestion in health and disease. Journal of Clinical Gastroenterology 1999, 28:3-10.
11. Mascarenhas M., Maqbool A. Gastrointestinal complications of cystic fibrosis. Cystic fibrosis 2010, 266-284. Informa Healthcare. first ed. J.L. Allen, H.B. Panitch, R.C. Ruberstein (Eds.).
12. Littlewood J.M., Wolfe S.P., Conway S.P. Diagnosis and treatment of intestinal malabsorption in cystic fibrosis. Pediatric Pulmonology 2006, 41:35-49.
13. CFA Cystic fibrosis in Australia 2009: 12th annual report from the Australian Cystic Fibrosis Data Registry. Annual report 2011, March, Cystic Fibrosis Australia, Sydney, Report No.: 1447-3933.
14. -/- mice. Proceedings of the National Academy of Sciences of the United States of America 1999, 96:13995-14000.
15. Mimoun M., Coste T.C., Lebacq J., et al. Increased tissue arachidonic acid and reduced linoleic acid in a mouse model of cystic fibrosis are reversed by supplemental glycerophospholipids enriched in docosahexaenoic acid. Journal of Nutrition 2009, 139:2358-2364.
16. -/- knockout mice. Metabolism: Clinical and Experimental 2006, 55:1192-1200.
17. Coste T.C., Deumer G., Reychler G., et al. Influence of pancreatic status and sex on polyunsaturated fatty acid profiles in cystic fibrosis. Clinical Chemistry 2008, 54:388-395.
18. tm1hgu/tm1hgu cystic fibrosis mouse. Pediatric Research 2003, 53:447-454.
19. Werner A., Bongers M.E.J., Bijvelds M.J., et al. No indications for altered essential fatty acid metabolism in two murine models for cystic fibrosis. Journal of Lipid Research 2004, 45:2277-2286.
20. Layer P., Gröger G. Fate of pancreatic enzymes in the human intestinal lumen in health and pancreatic insufficiency. Digestion 1993, 54:10-14.
21. Toouli J., Biankin A.V., Oliver M.R., et al. Management of pancreatic exocrine insufficiency: Australasian pancreatic club recommendations. Medical Journal of Australia 2010, 193:461-467.
22. Ferrie S., Graham C., Hoyle M. Pancreatic enzyme supplementation for patients receiving enteral feeds. Nutrition in Clinical Practice 2011, 26:349-351.
23. Anthony H., Collins C.E., Davidson G., et al. Pancreatic enzyme replacement therapy in cystic fibrosis: Australian guidelines. Journal of Paediatrics and Child Health 1999, 35:125-129.
24. FDA approves two new pancreatic enzyme products to aid food digestion 2012, U.S. Food and Drug Administration, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm294143.htm [accessed 19.03.12].
25. Gregory P.C. Gastrointestinal pH, motility/transit and permeability in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1996, 23:513-523.
26. Cox K.L., Isenberg J.N., Ament M.E. Gastric acid hypersecretion in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1982, 1:559-565.
27. Hallberg K., Abrahamsson H., Dalenbäck J., et al. Gastric secretion in cystic fibrosis in relation to the migrating motor complex. Scandinavian Journal of Gastroenterology 2001, 36:121-127.
28. Sidani S.M., Kirchhoff P., Socrates T., et al. δF508 mutation results in impaired gastric acid secretion. Journal of Biological Chemistry 2007, 282:6068-6074.
29. Schubert M.L. Gastric secretion. Current Opinion in Gastroenterology 2010, 26:598-603.
30. Kalnins D., Ellis L., Corey M., et al. Enteric-coated pancreatic enzyme with bicarbonate is equal to standard enteric-coated enzyme in treating malabsorption in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2006, 42:256-261.
31. DiMagno E.P. Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. Best Practice and Research. Clinical Gastroenterology 2001, 15:477-486.
32. Domínguez-Muñoz J. Pancreatic enzyme replacement therapy for pancreatic exocrine insufficiency: when is it indicated, what is the goal and how to do it?. Advances in Medical Sciences 2011, 56:1-5.
33. Ng S.M., Francini A.J. Drug therapies for reducing gastric acidity in people with cystic fibrosis. Cochrane Database of Systematic Reviews 2003, 2.
34. Brownlee I.A. The physiological roles of dietary fibre. Food Hydrocolloids 2011, 25:238-250.
35. Kaur S., Norkina O., Ziemer D., et al. Acidic duodenal pH alters gene expression in the cystic fibrosis mouse pancreas. American Journal of Physiology - Gastrointestinal and Liver Physiology 2004, 287:G480-G490.
36. - exchange in the villous epithelium of intact murine duodenum. American Journal of Physiology - Gastrointestinal and Liver Physiology 2005, 288:G1241-G1251.
37. - secretion. Acta Physiologica Scandinavica 2008, 193:357-365.
38. Minagawa N., Nagata J., Shibao K., et al. Cyclic AMP regulates bicarbonate secretion in cholangiocytes through release of ATP into bile. Gastroenterology 2007, 133:1592-1602.
39. Ameen N.A., Ardito T., Kashgarian M., et al. A unique subset of rat and human intestinal villus cells express the cystic fibrosis transmembrane conductance regulator. Gastroenterology 1995, 108:1016-1023.
40. Hogan D.L., Crombie D.L., Isenberg J.I., et al. Acid-stimulated duodenal bicarbonate secretion involves a CFTR-mediated transport pathway in mice. Gastroenterology 1997, 113:533-541.
41. Kaunitz J., Akiba Y. Acid-sensing protective mechanisms of duodenum. Journal of Physiology and Pharmacology 2004, 54:19-26.
42. Borowitz D., Durie P.R., Clarke L.L., et al. Gastrointestinal outcomes and confounders in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2005, 41:273-285.
43. Pratha V.S., Hogan D.L., Martensson B.A., et al. Identification of transport abnormalities in duodenal mucosa and duodenal enterocytes from patients with cystic fibrosis. Gastroenterology 2000, 118:1051-1060.
44. Debray D., Rainteau D., Barbu V., et al. Defects in gallbladder emptying and bile acid homeostasis in mice with cystic fibrosis transmembrane conductance regulator deficiencies. Gastroenterology 2012, 142:1581-1591.
45. Freudenberg F., Broderick A.L., Yu B.B., et al. Pathophysiological basis of liver disease in cystic fibrosis employing a δF508 mouse model. American Journal of Physiology - Gastrointestinal and Liver Physiology 2008, 294:G1411-G1420.
46. Taylor C.J., Hillel P.G., Ghosal S., et al. Gastric emptying and intestinal transit of pancreatic enzyme supplements in cystic fibrosis. Archives of Disease in Childhood 1999, 80:149-152.
47. Vandermeers A., Vandermeers-Piret M.C., Rathé J., et al. On human pancreatic triacylglycerol lipase: isolation and some properties. Biochimica et Biophysica Acta: Enzymology 1974, 370:257-268.
48. Matsuura K., Ogawa M., Kosaki G., et al. Proteochemical, immunological and enzymatic properties of two amylase components from human pancreatic juice. Clinical Biochemistry 1983, 16:224-228.
49. Alpers D.H., Tedesco F.J. The possible role of pancreatic proteases in the turnover of intestinal brush border proteins. Biochimica et Biophysica Acta: Biomembranes 1975, 401:28-40.
50. Gilbert J., Kelleher J., Littlewood J.M., et al. Ileal pH in cystic fibrosis. Scandinavian Journal of Gastroenterology 1988, 23:132-134.
51. Uchiyama H., Hayashi H., Tanji K.-i., et al. pH stat studies on bicarbonate secretion in the isolated mouse ileum. Biomedical Research 2007, 28:239-246.
52. Bentur L., Hino B., Shamir R., et al. Impaired gastric myolectrical activity in patients with cystic fibrosis. Journal of Cystic Fibrosis 2006, 5:187-191.
53. Collins C.E., Francis J.L., Thomas P., et al. Gastric emptying time is faster in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1997, 25:492-498.
54. Kuo P., Stevens J.E., Russo A., et al. Gastric emptying, incretin hormone secretion, and postprandial glycemia in cystic fibrosis-effects of pancreatic enzyme supplementation. Journal of Clinical Endocrinology and Metabolism 2011, 96:E851-E855.
55. Pauwels A., Blondeau K., Mertens V., et al. Gastric emptying and different types of reflux in adult patients with cystic fibrosis. Alimentary Pharmacology and Therapeutics 2011, 34:799-807.
56. Feinle-bisset C., Horowitz M. Dietary factors in functional dyspepsia. Neurogastroenterology and Motility 2006, 18:608-618.
57. Hallberg K., Fändriks L., Strandvik B. Duodenogastric bile reflux is common in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 2004, 38:312-316.
58. Schmidt K.D., Abiodun P., Tolckmitt W. Viscosity and electrolyte concentrations in gastric juice from cystic fibrosis children compared to healthy children. European Journal of Pediatrics 1981, 136:193-197.
59. Siomiany B.L., Murty V.L.N., Carter S.R., et al. Effect of covalently bound fatty acids and associated lipids on the viscosity of gastric mucus glycoprotein in cystic fibrosis. Digestion 1986, 34:275-280.
60. Ameen N., Alexis J., Salas P. Cellular localization of the cystic fibrosis transmembrane conductance regulator in mouse intestinal tract. Histochemistry and Cell Biology 2000, 114:69-75.
61. Pencharz P.B., Durie P.R. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clinical Nutrition 2000, 19:387-394.
62. Ganong W.F. Section V. Gastrointestinal function. Review of medical physiology 2005, 384-393. McGraw-Hill Medical, New York. 12th ed. W.F. Ganong (Ed.).
63. Thompson G.N., Davidson G.P. In vivo bile acid uptake from terminal ileum in cystic fibrosis. Pediatric Research 1988, 23:323-328.
64. Fondacaro J.D., Heubi J.E., Kellogg F.W. Intestinal bile acid malabsorption in cystic fibrosis: a primary mucosal cell defect. Pediatric Research 1982, 16:494-498.
65. Fondacaro J.D. Influence of dietary lipids on intestinal bile acid absorption. Experimental Biology and Medicine 1983, 173:118-124.
66. O'Brien S., Mulcahy H., Fenlon H., et al. Intestinal bile acid malabsorption in cystic fibrosis. Gut 1993, 34:1137-1141.
67. Stelzner M., Somasundaram S., Lee S., et al. Ileal mucosal bile acid absorption is increased in Cftr knockout mice. BMC Gastroenterology 2001, 1:10.
68. Wouthuyzen-Bakker M., Bodewes F.A.J.A., Verkade H.J. Persistent fat malabsorption in cystic fibrosis: lessons from patients and mice. Journal of Cystic Fibrosis 2011, 10:150-158.
69. Peretti N., Roy C.C., Drouin E., et al. Abnormal intracellular lipid processing contributes to fat malabsorption in cystic fibrosis patients. American Journal of Physiology - Gastrointestinal and Liver Physiology 2006, 290:G609-G615.
70. Holmes R., Lobley R. Intestinal brush border revisited. Gut 1989, 30:1667-1678.
71. Triadou N., Bataille J., Schmitz J. Longitudinal study of the human intestinal brush border membrane proteins. Distribution of the main disaccharidases and peptidases. Gastroenterology 1983, 85:1326-1332.
72. Skovbjerg H. Immunoelectrophoretic studies on human small intestinal brush border proteins-the longitudinal distribution of peptidases and disaccharidases. Clinica Chimica Acta 1981, 112:205-212.
73. Bai J.P.F. Distribution of brush-border membrane peptidases along the rat intestine. Pharmaceutical Research 1994, 11:897-900.
74. Antonowicz I., Reddy V., Khaw K.-T., et al. Lactase deficiency in patients with cystic fibrosis. Pediatrics 1968, 42:492-500.
75. Eggermont E. Gastrointestinal manifestations in cystic fibrosis. European Journal of Gastroenterology and Hepatology 1996, 8:731-738.
76. Morin C.L., Roy C.C., Lasalle R., et al. Small bowel mucosal dysfunction in patients with cystic fibrosis. Journal of Pediatrics 1976, 88:213-216.
77. Van Biervliet S., Eggermont E., Carchon H., et al. Small intestinal brush border enzymes in cystic fibrosis. Acta Gastroenterologica Belgica 1999, 62:267-271.
78. Madry E., Fidler E., Sobczynska-Tomaszewska A., et al. Mild CFTR mutations and genetic predisposition to lactase persistence in cystic fibrosis. European Journal of Human Genetics 2011, 19:748-752.
79. Madry E., Lisowska A., Minarowska A., et al. Lactose intolerance is a risk factor for decreased bone mineral density in pancreatic insufficient cystic fibrosis children. Journal of Cystic Fibrosis 2011, 10(Suppl. 1):S78.
80. Di Stefano M., Veneto G., Malservisi S., et al. Lactose malabsorption and intolerance and peak bone mass. Gastroenterology 2002, 122:1793-1799.
81. Aris R.M., Ontjes D.A., Buell H.E., et al. Abnormal bone turnover in cystic fibrosis adults. Osteoporosis International 2002, 13:151-157.
82. Frase L.L., Strickland A.D., Kachel G.W., et al. Enhanced glucose absorption in the jejunum of patients with cystic fibrosis. Gastroenterology 1985, 88:478-484.
83. Baxter P., Goldhill J., Hardcastle J., et al. Enhanced intestinal glucose and alanine transport in cystic fibrosis. Gut 1990, 31:817-820.
84. Milla P.J., Kilby A., Rassam U.B., et al. Small intestinal absorption of amino acids and a dipeptide in pancreatic insufficiency. Gut 1983, 24:818-824.
85. Lapey A., Kattwinkel J., di Sant'Agnese P.A., et al. Steatorrhea and azotorrhea and their relation to growth and nutrition in adolescents and young adults with cystic fibrosis. Journal of Pediatrics 1974, 84:328-334.
86. Shmerling D., Forrer J., Prader A. Fecal fat and nitrogen in healthy children and in children with malabsorption or maldigestion. Pediatrics 1970, 46:690-695.
87. tgh(neoim)hgu mouse model. Journal of Comparative Physiology B 2008, 178:705-712.
88. Shao J., Carmel R., Alpers D. Production of ectopic gastric intrinsic factor in gastric mucosa of humans with chronic gastritis. Digestive Diseases and Sciences 2011, 56:3209-3219.
89. Naimi D., Guéant J.L., Hambaba L., et al. Gastric intrinsic factor hypersecretion stimulated by pentagastrin in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1987, 6:899-903.
90. Monin B., Gueant J.L., Gerard A., et al. Physicochemical characterization and biological activity of intrinsic factor in cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1990, 10:87-94.
91. 12 deficiency in cystic fibrosis. New England Journal of Medicine 1973, 289:329.
92. Norkina O., Kaur S., Ziemer D., et al. Inflammation of the cystic fibrosis mouse small intestine. American Journal of Physiology - Gastrointestinal and Liver Physiology 2004, 286:G1032-G1041.
93. Van Biervliet S., Eggermont E., Marien P., et al. Combined impact of mucosal damage and of cystic fibrosis on the small intestinal brush border enzyme activities. Acta Clinica Belgica 2003, 58:220-224.
94. Brun L., Brance M., Rigalli A. Luminal calcium concentration controls intestinal calcium absorption by modification of intestinal alkaline phosphatase activity. British Journal of Nutrition 2012, 108:229-233.
95. Aris R.M., Merkel P.A., Bachrach L.K., et al. Consensus statement: guide to bone health and disease in cystic fibrosis. Journal of Clinical Endocrinology and Metabolism 2005, 90:1888-1896.
96. De Lisle R.C. Altered transit and bacterial overgrowth in the cystic fibrosis mouse small intestine. American Journal of Physiology - Gastrointestinal and Liver Physiology 2007, 293:G104-G111.
97. Coleman J.P., Hudson L.L. Cloning and characterization of a conjugated bile acid hydrolase gene from clostridium perfringens. Applied and Environment Microbiology 1995, 61:2514-2520.
98. Norkina O., Burnett T.G., De Lisle R.C. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infection and Immunity 2004, 72:6040-6049.
99. Quigley E.M.M., Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology 2006, 130:S78-S90.
100. De Lisle R.C., Sewell R., Meldi L. Enteric circular muscle dysfunction in the cystic fibrosis mouse small intestine. Neurogastroenterology and Motility 2010, 22:341-387.
101. Jakab R.L., Collaco A.M., Ameen N.A. Characterization of CFTR high expresser cells in the intestine. American Journal of Physiology - Gastrointestinal and Liver Physiology 2013, 305:G453-G465.
102. Bruzzese E., Raia V., Gaudiello G., et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Alimentary Pharmacology and Therapeutics 2004, 20:813-819.
103. Livnat G., Bentur L., Kuzmisnsky E., et al. Salivary profile and oxidative stress in children and adolescents with cystic fibrosis. Journal of Oral Pathology and Medicine 2010, 39:16-21.
104. Roulet M., Weber A.M., Paradis Y., et al. Gastric emptying and lingual lipase activity in cystic fibrosis. Pediatric Research 1980, 14:1360-1362.
105. Fredrikzon B., Blackberg L. Lingual lipase: an important lipase in the digestion of dietary lipids in cystic fibrosis?. Pediatric Research 1980, 14:1387-1390.
106. Abrams C.K., Hamosh M., Hubbard V.S., et al. Lingual lipase in cystic fibrosis. Quantitation of enzyme activity in the upper small intestine of patients with exocrine pancreatic insufficiency. Journal of Clinical Investigation 1984, 73:374-382.
107. DeNigris S.J., Hamosh M., Kasbekar D.K., et al. Lingual and gastric lipases: species differences in the origin of prepancreatic digestive lipases and in the localization of gastric lipase. Biochimica et Biophysica Acta: Lipids and Lipid Metabolism 1988, 959:38-45.
108. Hamosh M. Lingual and gastric lipases. Nutrition 1990, 6:421-428.
109. Armand M., Hamosh M., Philpott J.R., et al. Gastric function in children with cystic fibrosis: effect of diet on gastric lipase levels and fat digestion. Pediatric Research 2004, 55:457-465.
110. Gargouri Y., Moreau H., Pieroni G., et al. Human gastric lipase: a sulfhydryl enzyme. Journal of Biological Chemistry 1988, 263:2159-2162.
111. Carrière F., Grandval P., Renou C., et al. Quantitative study of digestive enzyme secretion and gastrointestinal lipolysis in chronic pancreatitis. Clinical Gastroenterology and Hepatology 2005, 3:28-38.
112. Matel J.L. Nutritional management of cystic fibrosis. Journal of Parenteral and Enteral Nutrition 2012, 36:60S-67S.
113. Li L., Somerset S. The clinical significance of the gut microbiota in cystic fibrosis and the potential for dietary therapies. Clinical Nutrition 2014, 33:571-580.
114. Jørgensen J.R., Fitch M.D., Mortensen P.B., et al. Absorption and metabolism of octanoate by the rat colon in vivo: concentration dependency and influence of alternative fuels. Gut 2002, 51:76-81.
115. Brulet M., Seyer A., Edelman A., et al. Lipid mapping of colonic mucosa by cluster TOF-SIMS imaging and multivariate analysis in cftr knockout mice. Journal of Lipid Research 2010, 51:3034-3045.
116. Nordgaard I., Mortensen P.B. Digestive processes in the human colon. Nutrition 1995, 11:37-45.
117. O'Keefe S.J. Nutrition and colonic health: the critical role of the microbiota. Current Opinion in Gastroenterology 2008, 24:51-58.
118. Vaisman N., Tabachnik E., Sklan D. Short-chain fatty acid absorption in patients with cystic fibrosis. Journal of Pediatric Gastroenterology and Nutrition 1992, 15:146-149.
119. Tolhurst G., Heffron H., Lam Y.S., et al. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 2012, 61:364-371.
120. DeVadder F., Kovatcheva-Datchary P., Goncalves D., et al. Microbiota-generated metabolites promote metabolic benefits via gut-brain neural circuits. Cell 2014, 156:84-96.
121. Malmberg E.K., Noaksson K.A., Phillipson M., et al. Increased levels of mucins in the cystic fibrosis mouse small intestine, and modulator effects of the Muc1 mucin expression. American Journal of Physiology - Gastrointestinal and Liver Physiology 2006, 291:G203-G210.
122. De Cruz P., Prideaux L., Wagner J., et al. Characterization of the gastrointestinal microbiota in health and inflammatory bowel disease. Inflammatory Bowel Diseases 2012, 18:372-390.
123. Canale-Zambrano J.C., Poffenberger M.C., Cory S.M., et al. Intestinal phenotype of variable-weight cystic fibrosis knockout mice. American Journal of Physiology - Gastrointestinal and Liver Physiology 2007, 293:G222-G229.
124. Bruzzese E., Callegari M.L., Raia V., et al. Disrupted intestinal microbiota and intestinal inflammation in children with cystic fibrosis and its restoration with lactobacillus GG: a randomised clinical trial. PLOS ONE 2014, 9:e87796.
125. Duytschaever G., Huys G., Bekaert M., et al. Cross-sectional and longitudinal comparisons of the predominant fecal microbiota compositions of a group of pediatric patients with cystic fibrosis and their healthy siblings. Applied and Environment Microbiology 2011, 77:8015-8024.
126. Duytschaever G., Huys G., Bekaert M., et al. Dysbiosis of bifidobacteria and Clostridium cluster XIVa in the cystic fibrosis fecal microbiota. Journal of Cystic Fibrosis 2013, 12:206-215.
127. Oliver C., Watson H. Omega-3 fatty acids for cystic fibrosis. Cochrane Database of Systematic Reviews 2013, 10.1002/14651858.CD002201.pub4.
128. Mil-Homens D., Bernardes N., Fialho A.M. The antibacterial properties of docosahexaenoic omega-3 fatty acid against the cystic fibrosis multiresistant pathogen Burkholderia cenocepacia. FEMS Microbiology Letters 2012, 328:61-69.
129. Jumpsen J.A., Brown N.E., Thomson A.B.R., et al. Fatty acids in blood and intestine following docosahexaenoic acid supplementation in adults with cystic fibrosis. Journal of Cystic Fibrosis 2006, 5:77-84.
130. Lloyd-Still J.D., Powers C.A., Hoffman D.R., et al. Bioavailability and safety of a high dose of docosahexaenoic acid triacylglycerol of algal origin in cystic fibrosis patients: a randomized, controlled study. Nutrition 2006, 22:36-46.
131. Olveira G., Olveira C., Acosta E., et al. Fatty acid supplementation improves respiratory, inflammatory and nutritional parameters in adults with cystic fibrosis. Archivos de Bronconeumologia 2010, 46:70-77.
132. Van Biervliet S., Devos M., Delhaye T., et al. Oral DHA supplementation in δF508 homozygous cystic fibrosis patients. Prostaglandins Leukotrienes and Essential Fatty Acids 2008, 78:109-115.
133. Al-Turkmani M.R., Andersson C., Alturkmani R., et al. A mechanism accounting for the low cellular level of linoleic acid in cystic fibrosis and its reversal by DHA. Journal of Lipid Research 2008, 49:1946-1954.
134. Katrangi W., Lawrenz J., Seegmiller A., et al. Interactions of linoleic and alpha-linolenic acids in the development of fatty acid alterations in cystic fibrosis. Lipids 2013, 48:333-342.
135. Umunakwe O.C., Seegmiller A.C. Abnormal n-6 fatty acid metabolism in cystic fibrosis is caused by activation of AMP-activated protein kinase. Journal of Lipid Research 2014, 10.1194/jlr.M050369.
136. De Boeck K., Kent L., Davies J., et al. CFTR biomarkers: time for promotion to surrogate end-point. European Respiratory Journal 2013, 41:203-216.
137. Derichs N., Sanz J., Von Kanel T., et al. Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data. Thorax 2010, 65:594-599.
138. - secretion in human rectal biopsies constitute a robust biomarker for cystic fibrosis diagnosis and prognosis. PLOS ONE 2012, 7:e47708.
139. DAA Australasian clinical practice guidelines for nutrition in cystic fibrosis 2006, Dietitians Association Australia.
140. Penque D. Proteomic biomarker discovery for the monogenic disease cystic fibrosis. Expert Review of Proteomics 2007, 4:199-209.